Grant of US patent strengthens the PharmaTher’s intellectual property portfolio covering novel uses and delivery forms of ketamine Announced positive efficacy and safety data from Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease patients, with 100% of patients treated with ketamine demonstrating a reduction in dyskinesias as measured by…


Previous articleInflammation Nation: How Psychedelics Could Combat Widespread Chronic Pain
Next articleMindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio